Where Zymergen Stands With Analysts
Within the last quarter, Zymergen (NASDAQ:ZY) has observed the following analyst ratings:
Last 30 Days
1 Month Ago
2 Months Ago
Mid-Morning Market Update: Markets Mostly Lower; General Motors Tops Q2 Views
Following the market opening Wednesday, the Dow traded down 0.44% to 34,962.94 while the NASDAQ rose 0.03% to 14,765.20. The S&P also fell, dropping 0.23% to 4,412.83.
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's morning session saw 58 companies set new 52-week lows.
Why Zymergen Shares Are Getting Slammed Today
Zymergen Inc (NASDAQ: ZY) is trading significantly lower Wednesday morning after the company provided a business update regarding its commercial product pipeline and financial forecast.
B of A Securities Downgrades Zymergen to Underperform, Lowers Price Target to $7
B of A Securities analyst Derik De Bruin downgrades Zymergen (NASDAQ:ZY) from Buy to Underperform and lowers the price target from $43 to $7.
The Daily Biotech Pulse: Pfizer’s Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 3)
10 Biggest Price Target Changes For Wednesday
Baird boosted the price target for Lululemon Athletica Inc. (NASDAQ: LULU) from $395 to $435. Lululemon shares rose 0.2% to $408.30 in pre-market trading.
Cowen & Co. Downgrades Zymergen to Market Perform
Cowen & Co. analyst Doug Schenkel downgrades Zymergen (NASDAQ:ZY) from Outperform to Market Perform.